Cross-Neutralizing Anti-Chikungunya and Anti-Dengue 2 IgG Antibodies from Patients and BALB/c Mice against Dengue and Chikungunya Viruses.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI
    • Subject Terms:
      Chikungunya virus*/immunology ; Antibodies, Neutralizing*/immunology ; Antibodies, Neutralizing*/blood ; Immunoglobulin G*/blood ; Immunoglobulin G*/immunology ; Antibodies, Viral*/immunology ; Antibodies, Viral*/blood ; Dengue*/immunology ; Dengue*/virology ; Dengue Virus*/immunology ; Mice, Inbred BALB C* ; Chikungunya Fever*/immunology ; Chikungunya Fever*/virology ; Cross Reactions*/immunology; Animals ; Humans ; Mice ; Mexico ; Female ; Neutralization Tests ; Male ; Coinfection/immunology ; Coinfection/virology ; Adult
    • Abstract:
      Dengue (DENV) and Chikungunya (CHIKV) viruses can be transmitted simultaneously by Aedes mosquitoes, and there may be co-infections in humans. However, how the adaptive immune response is modified in the host has yet to be known entirely. In this study, we analyzed the cross-reactivity and neutralizing activity of IgG antibodies against DENV and CHIKV in sera of patients from the Mexican Institute of Social Security in Veracruz, Mexico, collected in 2013 and 2015 and using IgG antibodies of BALB/c mice inoculated with DENV and/or CHIKV. Mice first inoculated with DENV and then with CHIKV produced IgG antibodies that neutralized both viruses. Mice were inoculated with CHIKV, and then with DENV; they had IgG antibodies with more significant anti-CHIKV IgG antibody neutralizing activity. However, the inoculation only with CHIKV resulted in better neutralization of DENV2. In sera obtained from patients in 2013, significant cross-reactivity and low anti-CHIKV IgG antibody neutralizing activity were observed. In CHIKV-positive 2015 sera, the anti-DENV IgG antibody neutralizing activity was high. These results suggest that CHIKV stimulates DENV2-induced memory responses and vice versa. Furthermore, cross-reactivity between the two viruses generated neutralizing antibodies, but exchanging CHIKV for DENV2 generated a better anti-CHIKV neutralizing response.
    • References:
      Viruses. 2019 Aug 05;11(8):. (PMID: 31387277)
      Emerg Infect Dis. 2007 May;13(5):764-7. (PMID: 17553261)
      Arch Virol. 2021 Jul;166(7):1913-1920. (PMID: 33907861)
      Transfusion. 2013 Oct;53(10 Pt 2):2567-74. (PMID: 23176378)
      Nat Microbiol. 2019 May;4(5):854-863. (PMID: 30833735)
      Int J Infect Dis. 2020 Jun;95:167-173. (PMID: 32247051)
      Infect Genet Evol. 2015 Oct;35:134-41. (PMID: 26247719)
      Virology. 2009 Sep 15;392(1):103-13. (PMID: 19631955)
      Microbiol Immunol. 2017 Oct;61(10):433-441. (PMID: 28881485)
      Nat Microbiol. 2020 Jun;5(6):796-812. (PMID: 32367055)
      J Clin Microbiol. 2006 Apr;44(4):1295-304. (PMID: 16597854)
      Virulence. 2021 Dec;12(1):2814-2838. (PMID: 34696709)
      J Gen Virol. 2010 Sep;91(Pt 9):2249-53. (PMID: 20444995)
      Emerg Infect Dis. 2016 Oct;22(10):1804-7. (PMID: 27347760)
      Crit Rev Eukaryot Gene Expr. 2020;30(3):199-206. (PMID: 32749106)
      Lancet. 2024 Feb 17;403(10427):667-682. (PMID: 38280388)
      Nat Commun. 2017 May 19;8:15412. (PMID: 28524874)
      Infect Drug Resist. 2021 Oct 19;14:4291-4299. (PMID: 34703255)
      Viruses. 2022 May 05;14(5):. (PMID: 35632709)
      Rev Chilena Infectol. 2016 Aug;33(4):464-467. (PMID: 27905632)
      Front Immunol. 2023 Jun 02;14:1200195. (PMID: 37334355)
      Pathogens. 2023 Sep 06;12(9):. (PMID: 37764943)
      PLoS Negl Trop Dis. 2015 Jan 08;9(1):e3445. (PMID: 25568956)
      Nat Rev Immunol. 2020 Oct;20(10):633-643. (PMID: 32782358)
      Pathog Glob Health. 2014 Dec;108(8):349-55. (PMID: 25491436)
      PLoS One. 2014 Aug 11;9(8):e104915. (PMID: 25111394)
      Emerg Infect Dis. 2015 Nov;21(11):2070-3. (PMID: 26488312)
      J Virol. 2020 Sep 15;94(19):. (PMID: 32699087)
      Science. 1999 Dec 10;286(5447):2156-9. (PMID: 10591647)
      Traffic. 2013 Jan;14(1):25-35. (PMID: 22998156)
      J Immunol. 2013 Jun 15;190(12):6295-302. (PMID: 23670192)
      Genome Announc. 2015 May 07;3(3):. (PMID: 25953170)
      Virus Res. 2019 Dec;274:197770. (PMID: 31626874)
      Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. (PMID: 22499787)
      J Immunol Methods. 2019 Oct;473:112630. (PMID: 31301278)
      Viral Immunol. 2020 May;33(4):266-276. (PMID: 31851873)
    • Contributed Indexing:
      Keywords: Alphavirus; Chikungunya virus; Flavivirus; arbovirus; co-infection; cross-reactivity; dengue virus; neutralizing capacity
    • Accession Number:
      0 (Antibodies, Neutralizing)
      0 (Immunoglobulin G)
      0 (Antibodies, Viral)
    • Publication Date:
      Date Created: 20240727 Date Completed: 20240728 Latest Revision: 20240729
    • Publication Date:
      20240729
    • Accession Number:
      PMC11281444
    • Accession Number:
      10.3390/v16071098
    • Accession Number:
      39066260